note ||| Mol. Cells, Vol. 21, No. 2, pp. 269-275 |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_yes xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_header
note ||| Molecules |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_yes xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
note ||| and |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_yes xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
note ||| Cells |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_yes xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
note ||| ï¿½KSMCB 2006 |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_yes xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
title ||| Functional Annotation and Analysis of Korean Patented |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_largest0 xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_header
title ||| Biological Sequences Using Bioinformatics |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_largest0 xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
author ||| Byung Wook Lee1, Tae Hyung Kim, Seon Kyu Kim, Sang Soo Kim2, Gee Chan Ryu, and Jong Bhak* |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_larger xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_header
affiliation ||| National Genome Information Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 305-333, Korea; |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_larger xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_header
affiliation ||| 1 Department of Biosystems, Korea Advanced Institute of Science and Technology, Daejeon 305-701, Korea; |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_larger xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
affiliation ||| 2 Department of Bioinformatics, Soongsil University, Seoul 156-743, Korea. |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_larger xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
note ||| (Received December 27, 2005; Accepted March 3, 2006) |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_larger xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| A recent report of the Korean Intellectual Property Of- |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_header
bodyText ||| fice (KIPO) showed that the number of biological se- |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| quence-based patents is rapidly increasing in Korea. We |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| present biological features of Korean patented se- |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| quences though bioinformatic analysis. The analysis is |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| divided into two steps. The first is an annotation step in |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| which the patented sequences were annotated with the |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| Reference Sequence (RefSeq) database. The second is |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| an association step in which the patented sequences |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| were linked to genes, diseases, pathway, and biological |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| functions. We used Entrez Gene, Online Mendelian In- |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| heritance in Man (OMIM), Kyoto Encyclopedia of |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| Genes and Genomes (KEGG), and Gene Ontology (GO) |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| databases. Through the association analysis, we found |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| that nearly 2.6% of human genes were associated with |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| Korean patenting, compared to 20% of human genes in |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| the U.S. patent. The association between the biological |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| functions and the patented sequences indicated that |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| genes whose products act as hormones on defense re- |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| sponses in the extra-cellular environments were the |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| most highly targeted for patenting. The analysis data |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| are available at http://www.patome.net. |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
keyword ||| Keywords: BLAST Analysis; Gene-, Disease-, Pathway-, |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
keyword ||| and Biofunction-patent Association Maps; Korea Patented |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
keyword ||| Biological Sequences; RefSeq. |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
sectionHeader ||| Introduction |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_largest-1 xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| Recent advances in high-throughput sequencing tech- |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| nologies have enabled us to determine many genomic |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| sequences fast and cheaply (Collins et al., 2003). As ge- |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
note ||| * To whom correspondence should be addressed. |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
note ||| Tel: 82-42-879-8500; Fax: 82-42-879-8519 |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
email ||| E-mail: jong@kribb.re.kr |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| nomic sequences are accumulated, the number of patents |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| that includes nucleotide or amino acid sequences has been |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| constantly increasing (Benson et al., 2005; Rouse et al., |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| 2005). Filing a patent application is the key step to protect |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| such sequence intellectual property. The patent owners of |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| biological sequences can gain tremendous value and con- |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| trol over the exploitation of the biological sequences (Xu |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| et al., 2002). |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| In Korea, the number of patented biological sequences |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| has been increasing rapidly over the past decades. Accord- |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| ing to the KIPO report of October 2005, the office received |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| 6,485 sequence-related patent applications containing totals |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| of 126,130 nucleotide and 60,305 amino acid sequences. |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| On average, 100 biological sequences are filed each month. |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| National Genome Information Center (NGIC) receives the |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| patented sequences and their related patent data from KIPO |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| once a month. We have constructed a database web server |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| called Patome (http://www.patome.net) to provide keyword |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| and homology search services against the patented se- |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| quences (Kim and Lee, 2005). |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| In the industry and technology areas, patented biologi- |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| cal sequences are mainly applied to use in diagnosis, |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| therapeutic biomolecules, drug development, agriculture, |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| and chemical synthesis (Yoo et al., 2005). The mapping |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| information of patented sequences and biological re- |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| sources, such as gene and disease, provides an opportu- |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| nity for better understanding of bio-resourcesâ patentable |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| targets. Especially, patent-related gene information can be |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| used to determine whether a particular gene or disease has |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| been patented, to follow competitorsâ work, and to reveal |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| if a patent has been infringed upon. Recent studies on |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| gene patenting indicated that nearly 20% of the human |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| genome, or 4,382 of the known 23,688 human genes, |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
note ||| Abbreviations: KIPO, the Korean Intellectual of Patent Office; |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
note ||| GO, gene ontology; OMIM, Online Mendelian Inheritance on |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
note ||| Human. |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
note ||| 270	Analysis of Korean Patented Biological Sequences |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_yes xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| have been patented in the United State (Jensen and |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| Murray, 2005). However, there is little information on |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| gene relatedness of the Korean patented sequences. Fur- |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| thermore, no attempt has been made to study the Korean |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| patented sequences from a biological perspective to date, |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| that is, determining how many genes are patented, what |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| kinds of genes are patented, or which diseases are related |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| to a patent. In this report, a patented sequence or a se- |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| quence refers to that of nucleotide or amino acid whose |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| patent was issued at KIPO. |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| The aim of this study is to provide biological features |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| of Korean patented sequences. To do this, we analyzed the |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| patented sequences with bioinformatics methods. The |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| analysis is divided into two steps. The first is an annota- |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| tion step: that is, the sequences are assigned with known |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| proteins. To this end, BLAST algorithm (Altschul et al., |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| 1997) was used to identify sequenceâs function with the |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| RefSeq database (Pruitt et al., 2005). This similarity |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| search is a general method used to identify functions of |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| unknown sequences and to determine whether filed se- |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| quences are novel in patent offices (Dufresne and Duval, |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| 2004). The second is an association step. In this step, the |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| sequences were linked to genes, diseases, pathway, and |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| biological functions. The linking information can be rep- |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| resented as association maps in which the patented se- |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| quences are linked to the corresponding biological re- |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| sources. We constructed four kinds of association maps: |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| gene-, disease-, pathway-, and biofunction-patent maps. |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| From these association maps, we found that nearly 2.6% |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| human genes are patented in Korea, and genes responsible |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| for immune response and cell-cell interaction outside cells |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| are major targets for Korean patenting. We provide the |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| web interface for browsing and querying of the annotation |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| and association data from the Patome website. These data |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| will be updated every other month. |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
sectionHeader ||| Materials and Methods |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_largest-1 xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| Acquisition and preparation of the Korean patented se- |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| quences In accordance with the agreement between KIPO and the |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Korea Research Institute for Bioscience and Biotechnology |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| (KRIBB) on July 8, 2004, KIPO provides KRIBB with the Ko- |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| rean patented sequences and their related patent data once a |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| month. As of November 15, 2005, the number of acquired pat- |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| ented sequences is 126,130 nucleotide and 60,305 amino acid |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| sequences. The data format of the sequences is the World Intellec- |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| tual Property Organization (WIPO) standard ST25, which is the |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| standardization of the presentation of nucleotide and amino acid |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| sequence listings in international patent applications (Jones, 2003). |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| We extracted sequences from the ST25-formatted sequence listing |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| and converted them into FASTA format sequences for further |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| processing. Most of the acquired patent applications contain more |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| than one sequence. Therefore, to identify each sequence of a |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| patent application, we created a new patented sequence number |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| with the application number and sequence number which are con- |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| nected with â-A/â. The sequence number is from the âSEQ ID |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| NOâ field in the ST25-formatted sequence listing. For example, if |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| a sequence has an application number of â1019997000621â and a |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| sequence number of â30â, its sequence number is â1019997000621- |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| A/30â. |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Classification of the patented sequences There are several |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| patent classification methods, for instance, the International |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Patent Classification (IPC), the European patent CLAssification |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| (ECLA), and the US classification. These classifications are |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| based on the application topic or the area of technology. How- |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| ever, as far as sequence patents are concerned, the most impor- |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| tant point is whether they have biological function or not. |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Therefore, we divided the patented sequence into two groups: |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| cDNA (containing protein-coding regions) and primer (not con- |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| taining protein-coding region). In the Korean patented nucleo- |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| tide sequences, there is a large number of short fragments (&lt; 30 |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| bp), which are mostly primers or synthetic DNA. These are very |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| short and not directly related to protein-coding genes. Therefore, |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| they are classified as primer and are not subject to a similarity- |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| based annotation. The sequences longer than 30 base pairs are |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| considered cDNA and are subject to further analysis. According |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| to the nucleotide patent classification, we divided all the nucleo- |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| tide patent sequences into 68,382 primers and 57,733 cDNA. |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| For the Korean patented amino acid sequences, we considered |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| all the patented amino acid sequences gene products. Therefore, |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| all the amino acid sequences are subject to further analysis. |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Annotation step We developed an automated annotation pipe- |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| line to analyze the patented sequences (Fig. 1). The nucleotide |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| sequences classified as cDNA were compared with the RefSeq |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| database by using BLASTX. The BLASTX results were filtered |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| by a cutoff E-value of 1E-5. The detailed annotation procedure |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| is described as follows: 1) The patented nucleotide sequences |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| (classified as cDNA) were classified by their organism name. |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| RefSeq sequences were also divided into organism-specific |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| RefSeq which consists of sequences from the same organism. 2) |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| BLASTX was used to compare each classified nucleotide se- |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| quence against RefSeq with the same organism as query. The |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| sequences not covered by organism-specific RefSeq were com- |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| pared with the entire RefSeq. The sequences whose organism is |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| unknown or empty were also compared with the whole RefSeq. |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| 3) The function of the nucleotide sequences was assigned by |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| using the BLASTX best hit. The patented amino acid sequences |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| were annotated with RefSeq protein database by using BLASTP. |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| The BLASTP results were filtered by a cutoff E-value of 1E-5. |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| The annotation procedure for the patented amino acid sequences |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| was similar to that of the nucleotide annotation. |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Association step All RefSeq records have explicit cross-links to |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| Entrez Gene (Maglott et al., 2005) and, if existing, to OMIM or to |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| PubMed (Pruitt et al., 2005). Therefore, the RefSeq accession |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| numbers of the BLAST results served as a bridge to link the pat- |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| ented sequences and other biological database records. The link- |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
note ||| Byung Wook Lee et al.	271 |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
figureCaption ||| Fig. 1. Overview of annotation and analysis flow of the Korean |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
figureCaption ||| patented sequences. Patented nucleotide sequences are divided |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| into Primer and cDNA. cDNA are annotated with organism- |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| specific RefSeq or the entire RefSeq. Patented amino acid se- |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| quences are also annotated with organism-specific RefSeq or the |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| entire RefSeq. From the annotated data and biological databases |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| (Gene, GO, OMIM, KEGG), four kinds of association maps are |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| built: gene-, disease-, pathway-, and biofunction-patent. The an- |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| notation data and association can be searched and downloaded |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| from the Korean Patome Web server (http://www.patome.net). |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| ing information was represented by association maps. To build |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| association maps, we constructed a RefSeq-patent table by pars- |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| ing the BLAST results. Each entry of the RefSeq-patent table |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| consists of a RefSeq accession number and the corresponding |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| patented sequence numbers. For example, if three patented se- |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| quence numbers â1020007008582-A/9â, â1019997000621-A/1â, |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| and â1019890701432-A/4â were linked the same RefSeq acces- |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| sion number âNP_001992â in the BLAST output, âNP_001992â |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| has the three patented sequence numbers in the RefSeq-patent |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| table. This would mean that the RefSeq accession number |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| âNP_001992â was patented three times and linked to the three |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| patented sequence numbers. |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| We built four kinds of association maps: gene-, disease-, |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| pathway-, and biofunction-patent. When a patent for a sequence |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| is issued, it is referring to the organism specifically described in |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| the patent application. Therefore, sequences annotated only with |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| organism-specific RefSeq in the RefSeq-patent table were used |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| to build the maps. To build the gene-patent map, we downloaded |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| the Entrez Gene database from NCBIâs ftp site and extracted |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| gene information of major model organisms: Homo sapiens |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| (human), Mus musculus (mouse), Rattus norvegicus (rat), Oryza |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_larger xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_continue
bodyText ||| Sativa (rice), Bos Taurus (cow), and Escherichia coli. The gene- |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_continue
bodyText ||| patent map was constructed by combining the RefSeq-patent |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| table and the gene information. This table presents the associa- |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| tion between a gene symbol and a patented sequence number. It |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| also provides information about which genes or how many |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| genes are patented. |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| To construct the disease-patent map, we used the OMIM da- |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| tabase, which is the definitive catalog of all inheritable traits |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| known in humans. It covers classic genetic diseases, common |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| diseases not usually thought of as genetic, proteins and enzymes, |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| and even the separation between toes (Hamosh et al., 2005). As |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| mentioned, the RefSeq database has links to MIM ID in the |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| âdb_xrefâ field. This linking information allowed the construc- |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| tion of the disease-patent map, which presents a relationship |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| between an OMIM entry and a patented sequence number. Some |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| OMIM entries are known to relate to human cancers (Hamosh et |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| al., 2005). To obtain the comprehensive cancer-related OMIM |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| entries, we extracted cancer-associated OMIM entries computa- |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| tionally, confirmed them with manual curation, and created a |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| cancer-OMIM list. We added the âCancer-relatedâ field in the |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| disease-patent table and marked cancer-related-OMIM entries |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| with âcancerâ. The two association maps have links to RefSeq, |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Entrez Gene, and OMIM. The following is a typical example of |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| map construction. If a patented sequence number â10200100- |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| 51510-A/1â is linked to RefSeq accession number âNP _009225â |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| in the BLAST results, we know that the patent accession number |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| is associated with the gene name âBRCA1â and OMIM ID |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| â113705â from Entrez Gene, and RefSeq and the number is related |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| to a human cancer (breast cancer) from the cancer-OMIM list. |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Pathway-patent map is created by using Kyoto Encyclopedia |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| of Genes and Genomes (KEGG) GENES database, which is a |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| collection of gene catalogs for all the completely sequenced |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| genomes and some partial genomes with up-to-date annotation |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| of gene functions (Kanehisa et al., 2006). From KEGG GENES |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| database, we built a linking table between gene and pathway. |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| The linking table allowed the pathway-patent map, which pre- |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| sents a relationship between a KEGG ID and a patented se- |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| quence number. |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Biofunction-patent map is constructed by using GO, which is |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| composed of three subdivisions covering basic areas of biological |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| research: the molecular function of gene products, their role in |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| multi-step biological processes, and their physical structure as |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| cellular components (Gene Ontology Consortium, 2004). We used |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| the GO terms to categorize the biological information of the pat- |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| ented sequences. First, two kinds of files were downloaded from |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| the GO website (http://www.geneontology.org/): GO format files |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| and gene association files of the Compugenâs Gene Ontology |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| (Kim et al., 2004; Xie et al., 2002). From the GO format files, |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| information about relationships of the GO terms was extracted by |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| using its hierarchical structure. Protein sets were obtained from |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| the gene association files. Second, BLAST was used to compare |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| the patented sequences against the protein sets. From the BLAST |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| results and term relationships, we classified the patented se- |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| quences into the GOâs three categories (molecular function, bio- |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| logical process, and cellular component). |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
sectionHeader ||| Results |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_largest-1 xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| Statistics of applications for patented sequences Cur- |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
note ||| 272	Analysis of Korean Patented Biological Sequences |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_yes xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
tableCaption ||| Table 1. Top ten human gene entries in the gene-patent map. |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
table ||| Order	Gene name	Locus	Annotation	No. (%) of Patents |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
table ||| 1	FN1	2q34	Fibronectin 1	73 (2.8) |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| 2	APP	21q21.3	Amyloid beta A4 protein precursor	70 (2.7) |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| 3	NRG1	8p21-p 12	Neuregulin 1 isoform HRG-beta1	48 (1.9) |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| 4	LOC440871	2p11.2	Ig kappa variable region	46 (1.8) |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| 5	FGF2	4q26-q27	Fibroblast growth factor 2	45 (1.8) |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| 6	THPO	3q27	Thrombopoietin isoform 3 precursor	45 (1.8) |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| 7	CRH	8q13	Corticotropin releasing hormone precursor	41 (1.6) |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| 8	WT1	11p13	Wilms tumor 1 isoform D	34 (1.3) |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| 9	PYY	17q21.1	Peptide YY	33 (1.3) |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| 10	TP53	17p13.1	Tumor protein p53	32 (1.2) |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| rently, the number of sequence-based Korean patent appli- |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| cations is 6,485. They contain 186,435 sequences and were |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| submitted by 4,453 applicants. Of the top ten sequence |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| patent applicants, six are U.S.-based biotechnology compa- |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| nies, including Genset Co., Corixa Corperation, Genentech |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Inc., Ribozyme Pharmaceuticals Inc., Amgen Inc., and |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Trimeris Inc. The others are Germany-, Japan-, and Ko- |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| rean-based biotechnology companies, including Kyowa |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Hakko Kogyo Co., Basf Aktiengesellschaft, Medigenes, Inc, |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| and SJ HignTech Co. The sequences claimed by the top ten |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| applicants account for 30 percent (54,769) of the total pat- |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| ented sequences. The top sequence patent applicant is Gen- |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| set Co. whose patented sequences amount to 12,830. |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Analysis of annotation data and association maps From |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| the BLAST results in the annotation step, we assigned |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| 21,538 (37%) out of the patented nucleotide (cDNA) se- |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| quences and 29,489 (49%) patented amino acid sequences |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| with RefSeq and converted the annotation results into a |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| RefSeq-patent table. Of the 1,899,454 RefSeq sequences, |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| 13,665 were associated with Korean patenting. The most |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| frequently claimed RefSeq accession number was âNP_ |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| 057856â whose title is âthe precursor of an envelope sur- |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| face glycoprotein gp 160 in human immunodeficiency |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| virus 1â. âNP_057856â was claimed in 455 patented se- |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| quences. Although the current RefSeq (Release 13) in- |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| cludes 3,060 organisms including eukaryotes, bacteria, |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| and viruses, RefSeq does not provide a comprehensive |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| dataset representing the complete sequence information |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| for any given species (Pruitt et al., 2005). Accordingly, |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| because RefSeq is not comprehensive, even if a patented |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| sequence is originated from a gene, it may not be anno- |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| tated with RefSeq. |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| From the gene-patent map, we found that nearly 2.6% |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| of human genes were associated with Korean patenting. |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| This figure represents 613 of the 23,688 human genes at |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| the time of writing. FN1 (fibronectin 1 isoform 3 |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| preproprotein), and APP [amyloid beta (A4) precursor |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| protein] were the most highly patented human genes. The |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
tableCaption ||| Table 2. Statistics of patent-related genes in the major organ- |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
tableCaption ||| isms. |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| Organism	No. of total	No. (%) of patent-related |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
table ||| RefSeq proteins	RefSeq proteins |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| Human	23,658	613 (2.6) |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| Mouse	17,456	267 (1.5) |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| Rat	23,230	252 (1.1) |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| Rice	36,946	136 (0.4) |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| Cow	37,568	147 (0.4) |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| E. coli	4,237	118 (2.8) |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| protein sequences of FN1 were claimed in 73 patent ap- |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| plications, and those of APP were claimed in 70. The top |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| ten human genes of the gene-patent map are given in Ta- |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| ble 1. We also analyzed the patent relatedness of major |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| model organismsâ genes and found that 1.5% of mouse |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| genes, 1.1 % of rat genes, 0.4% of rice genes, 0.4% of cow |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| genes, and 2.8% of E. coli genes were associated with |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Korean patenting. A summary of patent-related genes of |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| the major organisms is shown in Table 2. |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| From the disease-patent map, we found that 610 of the |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| 16,360 OMIM entries were associated with Korean pat- |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| enting. FN1 and ABCA1 (ATP-binding cassette) were the |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| most frequently patented disease genes. By comparing the |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| top ten entries of the disease-patent and the human gene- |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| patent map, we found that six entries (FN1, THPO, APP, |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| FGF2, NRG1 and WT1) were overlapping. This indicates |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| that disease- and health-related human genes were more |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| often filed and issued for patenting. Table 3 shows the top |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| ten OMIM entries of the disease-patent. |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| From the pathway-patent map, we found that 107 of |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| 281 KGEE pathways were associated with Korean patent- |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| ing. âcytokine-cytokine receptor interactionâ is the most |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| patent-related pathway, which claimed in 253 patent ap- |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| plications. Cytokine is an extracellular signal protein or |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| peptide that acts as a local mediator in cell-cell communi- |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| cation such as interferones, growth hormone, and prolac- |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
note ||| Byung Wook Lee et al. 	273 |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
tableCaption ||| Table 3. Top ten OMIM entries in the OMIM-patent map. |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| Order	OMIM ID	OMIM Title	No. (%) of patents |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| 1	135600	FIBRONECTIN 1; FN1	69 (3.3) |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| 2	600046	ATP-BINDING CASSETTE, SUBFAMILY A, MEMBER 1; ABCA1	69 (3.3) |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| 3	600044	THROMBOPOIETIN; THPO	48 (2.2) |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| 4	104760	AMYLOID BETA A4 PRECURSOR PROTEIN; APP	45 (1.9) |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| 5	103600	ALBUMIN; ALB	40 (1.8) |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| 6	134920	FIBROBLAST GROWTH FACTOR 2; FGF2	39 (1.5) |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| 7	142445	NEUREGULIN 1; NRG1	33 (1.3) |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| 8	139250	GROWTH HORMONE 1; GH1	29 (1.2) |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| 9	607102	WILMS TUMOR 1 GENE; WT1	27 (1.2) |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| 10	120150	COLLAGEN, TYPE I, ALPHA-1; COL1A1	25 (1.1) |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
tableCaption ||| Table 4. Top ten KEGG IDs in the pathway-patent map. |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
table ||| Order	KEGG ID	KEGG Title	No.(%) of patents |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
table ||| 1	hsa04060	Cytokine-cytokine receptor interaction	253 (10.8) |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| 2	hsa04810	Regulation of actin cytoskeleton	141 (6.0) |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| 3	hsa04512	ECM-receptor interaction	127 (5.4) |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| 4	hsa04010	MAPK signaling pathway	126 (5.4) |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| 5	hsa04510	Focal adhesion	125 (5.4) |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| 6	hsa04640	Hematopoietic cell lineage	107 (4.6) |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| 7	hsa01430	Cell Communication	105 (4.5) |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| 8	hsa04630	Jak-STAT signaling pathway	91 (3.9) |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| 9	hsa04080	Neuroactive ligand-receptor interaction	88 (3.8) |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| 10	hsa02010	ABC transporters	76 (3.3) |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| tin. The top ten KEGG IDs of the pathway-patent is given |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| in Table 4. |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Through the mapping the patented sequences to GO, |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| we were able to assign 16,905 patented sequences with |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| 719 GO accession numbers. As mentioned above, GO is |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| composed of three ontologies: molecular function, bio- |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| logical process, and cellular component. Therefore, the |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| 719 accession numbers were categorized into the three |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| ontologies. In the mapping to GO molecular function, we |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| assigned 15,845 sequences with 89 GO molecular func- |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| tion terms; found that major patent-target functions were |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| âPeptide hormoneâ, âimmunoglobulin receptorâ, and âstruc- |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| tural moleculeâ. We mapped 12,474 sequences to 363 GO |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| cellular component terms. This mapping showed that pro- |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| teins existing in extra-cellular environments or on mem- |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| branes were major targets for patenting. While proteins in |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| nuclei or cytoplasm are most abundant in cells, they were |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| not interesting targets for patenting. We mapped 14,756 |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| sequences to 237 GO biological processes terms. Three |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| terms, âdefense responseâ, âmacromolecule catabolismâ, |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| and âcell-cell signalingâ were major biological process |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| terms for patenting. Table 5 shows the top ten patent- |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| related GO terms according to the three ontologies. |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Validation of association Because the association maps |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| are created based on BLAST similarity between RefSeq |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| and patented sequences, we checked the validity of the |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| BLAST alignments to determine the accuracy of our analy- |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| sis. In the annotation step, the BLAST cutoff E-value of |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| 1E-5 was used to filter the BLAST results. It means that |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| statistically weaker alignments may be positioned near be- |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| low 1E-5. For these reasons, we randomly selected 30 |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| genes whose BLAST E-value belongs to the range between |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| 1E-5 and 1E-6 by a random number generating program. |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| We manually compared the selected genes with the titles or |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| abstracts of their matching patents to check whether the |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| name or function of a gene explicitly appeared in the title |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| or abstract of its corresponding patent. The result of the |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| comparison was represented as one of two relationships: |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| âtrueâ and âunknownâ. Although a âfalseâ relationship may |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| exist, we cannot determine whether a relationship is a real |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| âfalseâ or not. Therefore, we considered all the relationships |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| except âtrueâ as âunknownâ. |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| The following two gene examples show how to determine |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| the relationship. The first example is FCER1A, Fc fragment |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| of IgE, which was associated with two patents in the gene- |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| patent map: â1019997000621â and â1019890701432â and |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| whose titles are âFusion polypeptidesâ and âDNA encoding |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| IgE receptor alpha-subunit or fragment thereofâ, respec- |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| tively. In such cases, one patent titles contain FCER1A- |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| related terms, while the other title, âFusion polypeptidesâ, |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| does not show its relatedness to FCER1A. For the next step, |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| we acquired the abstract of â1019997000621â from the Ko- |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| rean Institute of Patent Information (KIPRIS) web server |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| (http://www.kipris.or.kr). The abstract was written in Ko- |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| rean. After reading the abstract, we could conclude that |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
note ||| 274	Analysis of Korean Patented Biological Sequences |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_yes xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
tableCaption ||| Table 5. Top ten GO categories of Korean patented sequences by biological process, molecular function, and cellular component. |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
table ||| Order	Biological process terms	No. of 	Molecular function terms	No. of 	Cellular component terms	No. of |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
table ||| patented 	patented 	patented |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| sequences	sequences	sequences |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| 1	Defense response	3043 (21)8	Peptide hormone	1956 (12)	Extracellular	5081 (41) |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| 2	Macromolecule catabolism	1022 (7)	Immunoglobulin receptor	1342 (8)	Integral membrane protein	1630 (13) |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| 3	Cell-cell signaling	1000 (7)	Structural molecule	1155 (7)	Extracellular space	1603 (13) |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| 4	Cell proliferation	857 (6)	Hematopoietin/interferon-class	660 (4)	Mitochondrion	1049 (8) |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| cytokine receptor ligand |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| 5	G-protein coupled receptor 	575 (4)	Serine-type peptidase	626 (4)	Integral plasma membrane 	1008 (8) |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| protein signaling pathway	protein |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| 6	Signal transduction	523 (4)	Cytokine	473 (3)	Membrane	882 (7) |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| 7	Macromolecule 	379 (3)	Growth factor	439 (3)	Cytoplasm	704 (6) |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| biosynthesis |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| 8	Transport	374 (3)	Adenyl nucleotide binding	354(2)	Soluble fraction	585 (5) |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| 9	Biological_process 	368 (2)	Receptor	348(2)	Extrachromosomal circular 	390 (3) |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| unknown	DNA |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| 10	Electron transport	351 (2)	Transcription factor	300(2)	Plasma membrane	364 (3) |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
tableCaption ||| ' Number of parenthesis represents the percentage of Korean patented sequences in the GO three categories. |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| â1019997000621â is related to FCER1A. Therefore, FCER1A |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| has two âtruesâ. Another example is ChGn, chondroitin |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| beta1,4 N-acetylgalactosaminyltrasferase. The gene-patent |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| map showed that it was associated with two patents: |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| â1020007013633â and â1020047000844â whose titles are |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| ânovel polypeptides and nucleic acids encoding the sameâ |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| and âpeptides effective in the treatment of tumors and other |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| conditions requiring the removal or destruction of cellsâ. |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| We could not determine whether the two patents are related |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| to ChGn from the titles or the abstracts of the two patents; |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| therefore, ChGn has two âunknownsâ. We investigated 70 |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| pairs of a gene and the corresponding patented sequences. |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Our comparison showed 48 âtrueâ relationships, with 22 |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| âunknownsâ. This result suggests that the similarity-based |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| method is useful for its identification of patents that claim |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| specific protein-coding sequences. |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Web service for annotation and association maps The |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| complete lists of the patent-related information on major |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| organismsâ genes, OMIM, KEGG, and GO terms are |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| available on the Korean Patome website. The Korean Pa- |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| tome can be accessed through web interface for browsing |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| and querying. The querying interface allows the user to |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| search against the annotation data and the association |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| maps. The annotation data can be searched according to |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| application number, public number, and applicant. The |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| mapping data search interfaces allow the user to search |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| for the gene name of a selected organism, OMIM ID, dis- |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| ease name, KEGG ID, and RefSeq accession number. The |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| search results can be saved to the userâs local disk as a |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| tab-delimited text file. The display of search results con- |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| tains outgoing links to external databases: RefSeq, OMIM, |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| and GO. |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| The entire contents of analysis data are also available |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| for download from the Patome website. The data are in |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| three formats: 1) simple tab-delimited text file (for easy |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| parsing of the data), 2) formatted flat text file that is eas- |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| ily read by humans as well as computers, and 3) MySQL |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| database dumps. |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
sectionHeader ||| Discussion |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_largest-1 xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| Our analysis suggests that nearly 2.6% of human genes |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| were related to Korean patenting. This percentage is small, |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| compared to that of gene-based U.S. patents. The patent |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| association studies of human genes and diseases show that |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| human health- and disease-related genes were major pat- |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| ent targets. They are mostly applied to diagnosis, thera- |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| peutic biomolecules, and drug development fields. The |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| biofunction-patent map indicates that many gene products |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| located in extra-cellular environments are applied to the |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| biotechnology and the pharmaceutical industry. This is |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| due to an easy access to the proteins outside cells. These |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| proteins were mainly involved in immune response, cell- |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| cell signaling, and cell proliferation. |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| The patented sequences described above are not a com- |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| prehensive set of the Korean patented sequences for the |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| following three reasons. First, not all of the claimed se- |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| quences are explicitly disclosed in patent specifications. |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| As a matter of fact, sequence patents are only implicitly |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| claimed without the actual sequences being disclosed. For |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| example, a sequence can be claimed by reference to citing |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| the Korean Collection for Type Culture (KCTC) deposit |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| number of a clone containing the sequence. Second, for |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| patents filed pre-1999, KIPO did not require nucleotide |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
note ||| Byung Wook Lee et al.	275 |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| sequences listed in patents to be submitted in a computer |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_largest-2 xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| readable format. The patented sequences filed before this |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_largest-2 xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| date were manually converted into electronic format in |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_largest-2 xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| 2000 by the KIPO staff. However, we could not know the |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_largest-2 xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| conversion criteria or accuracy, so we could not confirm |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_largest-2 xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| completeness of patented sequences filed before 1999. |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_largest-2 xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Third, a number of patent applications related to se- |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_largest-2 xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| quences are currently being examined at KIPO. These |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_largest-2 xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| patent applications and their sequences have not been |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_largest-2 xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| disclosed. The sequences of the unpublished applications |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_largest-2 xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| are not included in this study. |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_largest-2 xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Acknowledgments We thank Dr. YoungGyun Cho at KIPO for |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| helpful discussion. This work was supported by the Korean |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Ministry of Science and Technology under grant number M1- |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| 0437-01-0002 and Biogreen21 program of the Rural Develop- |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| ment Administration. This work was also supported by the |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| KRIBB Research Initiative Program. We thank Maryana Bhak |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| for editing the manuscript. |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
sectionHeader ||| References |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_largest-1 xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
reference ||| Altschul, S. F., Madden, T. L., Schï¿½ffer, A. A., Zhang, J., Zhang, |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
reference ||| Z., et al. (1997) Gapped BLAST and PSI-BLAST: a new |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| generation of protein database search programs. Nucleic Ac- |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| ids Res. 25, 3389-3402. |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
reference ||| Benson, D. A., Karsch-Mizrachi, I., Lipman, D. J., Ostell, J., |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
reference ||| and Wheeler, D. L. (2005) GenBank. Nucleic Acids Res. 33, |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| D34-D38. |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
reference ||| Collins, F. S., Green, E. D., Guttmacher, A. E., and Guyer, M. S. |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
reference ||| (2003) A vision for the future of genomics research. Nature |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 422, 835-847. |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
reference ||| Dufresne, G. and Duval, M. (2004) Genetic sequences: how are |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
reference ||| they patented? Nat. Biotech. 22, 231-232. |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
reference ||| Gene Ontology Consortium (2004) The gene ontology (GO) |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
reference ||| database and informatics resource. Nucleic Acids Res. 32, |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| D258-D261. |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
reference ||| Hamosh, A., Scott, A. F., Amberger, J. S., Bocchini, C. A., and |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
reference ||| McKusick, V. A. (2005) Online Mendelian Inheritance in |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| Man (OMIM), a knowledgebase of human genes and genetic |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| disorders. Nucleic Acids Res. 33, D514-D517. |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
reference ||| Jensen, K and Murray, F. (2005) Property landscape of the hu- |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
reference ||| man genome. Science 14, 239-240. |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
reference ||| Jones, R. (2003) Errors in patent application sequence listings. |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
reference ||| Nat. Biotech. 21, 1239-1240. |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_larger xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
reference ||| Kanehisa, M., Goto. S., Hattori, M., Aoki-Kinoshita, K. F., Itoh, |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
reference ||| M., et al. (2006) From genomics to chemical genomics: new |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| developments in KEGG. Nucleic Acids Res. 34, D354-D357. |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
reference ||| Kim, S. K. and Lee, B. W. (2005) Patome: Database of Patented |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
reference ||| Bio-sequences. Genomics &amp; Informatics 3, 94-97. |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_larger xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
reference ||| Kim, T. H., Jeon, Y. J., Yi, J. M., Kim, D. S., Huh, J. W., et al. |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
reference ||| (2004) The distribution and expression of HERV families in |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| the human genome. Mol. Cells 18, 87-93. |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
reference ||| Maglott, D., Ostell, J., Pruitt, K. D., and Tatusova, T. (2005) |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
reference ||| Entrez Gene: gene-centered information at NCBI. Nucleic |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| Acids Res. 33, D54-D58. |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
reference ||| Pruitt, K. D., Tatusova, T., and Maglott, D. R. (2005) NCBI |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
reference ||| Reference Sequence (RefSeq): a curated non-redundant se- |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| quence database of genomes, transcripts and proteins. Nu- |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| cleic Acids Res. 33, D501-D504. |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_larger xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
reference ||| Rouse, R. J. D., Castagnetto, J., and Niedner, R. H. (2005) Pat- |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
reference ||| Gen--a consolidated resource for searching genetic patented |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| sequences. Bioinformatics 21, 1707-1708. |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
reference ||| Xie, H., Wasserman, A., Levine, Z., Novik, A., Grebinskiy, V., et |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
reference ||| al. (2002) Large-scale protein annotation through gene on- |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| tology. Genome Res. 12, 785-794. |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
reference ||| Xu, G., Webster, A., and Doran, E. (2002) Patented sequence |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
reference ||| databases. World Patent Info. 24, 95-101. |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_larger xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
reference ||| Yoo, H., Ramanathan, C., and Barcelon-Yang, C. (2005) Intel- |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
reference ||| lectual property management of sequence information from a |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| patent searching perspective. World Patent Info. 27, 203-211. |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new

